Stroke-associated pneumonia research over the past 2 decades has yielded significant insight into SAP risk factors, diagnostic measures, and management strategies.
All articles by Brandon May
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Researchers sought to investigate the association between sleep-disordered breathing and sleep-related hypoxia with SARS-CoV-2 infection and COVID-19 outcomes.
Does the prescription of antibiotics provide a meaningful clinical benefit for children who present with uncomplicated lower respiratory tract infections?
Researchers examined health disparities in the duration of asthma exacerbations in patients post-COVID-19.
People with diabetes are at a higher risk of experiencing poor outcomes after contracting COVID-19, including hospitalization and death. Researchers expanded on a previous analysis to identify risk factors for short-term adverse outcomes among veterans with diabetes and COVID-19.
The prevalence of COVID-19 in patients with chilblain-like lesions is assessed.
COVID-19 can cause additional complications and even death in people with a pre-existing conditions like type 2 diabetes. Researchers studied whether the medications people with type 2 diabetes often take were associated with a risk of dying from the virus.
Researchers evaluated the safety and efficacy of the investigational, microbiota-based, live biotherapeutic RBX2660 for treatment of recurrent C difficile infection.
Investigators assessed the frequency and severity of adverse events associated with H pylori treatments in clinical practice.
A clinical trial of fostamatinib showed it was safe and effective for treating patients hospitalized with COVID-19 receiving oxygen.
Can treatment with autologous CoNS-AM+ suppress S. aureus survival and improve atopic dermatitis symptoms?
Researchers assessed the sex-specific association between self-reported sleep duration and mortality in an East Asian population.
Researchers investigated the prevalence, natural history, and clinical significance of pulmonary disease in outpatients with SARS-CoV-2.
A new algorithm offers guidance on when to start and stop noninvasive respiratory therapies for COVID-19.
A recent trial compared the efficacy of standard oral therapy for pulmonary TB with a dry powder inhaler containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin.
The rates of SARS-CoV-2 infection, hospitalization, and mortality in patients with or without AD are compared.
In order to assess asymptomatic infections and immunologic responses to COVID-19, a team of researchers tested for SARS-CoV-2 antibodies in a multiple sclerosis cohort.
The American College of Physicians has released guidance on the appropriate use of high-flow nasal oxygen in hospitalized patients with acute respiratory failure.
The American College of Physicians convened a panel to identify best practices for the use of short-course antibiotics in the management of common infections.
Investigators assessed the effectiveness of treatment with methylprednisolone vs dexamethasone for hospitalized COVID-19 patients with hypoxia.
The angiotensin converting enzyme 2 receptor, which enables entry of SARS-CoV-2 into lung epithelial cells, appears to mediate the severity of COVID-19 in patients COPD.
Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.
To help clinicians and patients determine if antibodies protect against reinfection, the ACP discussed tests for diagnosing and estimating the prevalence of COVID-19.
Researchers assessed the risk for severe COVID-19 in patients with microscopic colitis vs the general population.
Researchers conducted serum metabolomic analysis to see if ApoB:ApoA1 ratio is an accurate biomarker of cardiovascular disease risk in patients with juvenile systemic lupus erythematosus.
A team of researchers has developed the severe COVID-19 adaptive risk predictor (SCARP) calculator that reliably predicts the risk of progression to severe disease or death.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Indoor mold exposure and the presence of anti-Aspergillus antibodies may be linked to worsened lung function during exacerbations in COPD.
A study designed to evaluate the impact of coronavirus disease 2019 lockdown on people living with type 1 diabetes, shows patients were able to improve their glycemic control indices.